STOCK TITAN

electroCore, Inc. - ECOR STOCK NEWS

Welcome to our dedicated page for electroCore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on electroCore stock.

electroCore, Inc. (Nasdaq: ECOR) is a leading US-based bioelectronic medicine and wellness company, renowned for its pioneering non-invasive vagus nerve stimulation (nVNS) technology platform. Founded in 2005, electroCore specializes in developing patient-administered therapies aimed at treating a variety of conditions across neurology, psychiatry, gastroenterology, and other medical fields. The company’s flagship product, gammaCore, is FDA cleared for treating and preventing migraines and cluster headaches in adults, including adjunctive use for adolescent patients. Ongoing trials are exploring its efficacy in conditions such as epilepsy, gastric motility disorders, depression, and anxiety.

The company operates on a global scale, with headquarters in the US and additional offices in Germany, the UK, Italy, Australia, and Canada, employing more than 30 full-time consultants and specialists. electroCore's product portfolio also includes the Truvaga and TAC-STIM devices, designed to enhance general wellbeing and human performance. These devices are seeing increasing market adoption, as evidenced by the company's strong financial performance.

In 2023, electroCore reported a notable 87% increase in net sales, reaching $16 million, compared to $8.6 million in 2022. This growth was driven by higher sales of gammaCore in the US and internationally, along with expanding revenue from their non-prescription wellness products. The company also achieved a gross profit of $13.2 million with an 83% gross margin for the year. While research and development expenses saw a slight reduction, there were targeted investments to enhance the therapy delivery platform, including smartphone-integrated technologies.

electroCore continually strives to foster innovation and improve patient health outcomes. With their robust pipeline, strategic partnerships, and ongoing clinical trials, electroCore is well-positioned to maintain its leadership in the bioelectronic medicine sector. The company remains committed to delivering non-invasive, effective, and easily accessible treatments to improve the quality of life for patients worldwide.

Rhea-AI Summary

On August 4, 2021, electroCore announced the publication of an article in PharmacoEconomics that highlights the cost-effectiveness of gammaCore for treating cluster headaches. It shows that gammaCore therapy can save £450 per patient in the first year compared to standard treatments, while also reducing headache frequency and severity. The UK National Institute for Health and Care Excellence (NICE) guidance supports the adoption of gammaCore in the NHS, aiming to enhance its market presence. Iain Strickland noted the significance of NICE’s endorsement for growth in the UK market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary

On August 2, 2021, electroCore announced its participation in the Canaccord Genuity Growth Conference, set for August 10-12, 2021. The company's management will present on August 12 at 8:30 am EDT. This conference offers a platform for virtual one-on-one meetings with investors. Following the event, a recording of the presentation will be accessible on the investor section of the company's website. electroCore specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies for neurological conditions, including migraine and cluster headaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
conferences
-
Rhea-AI Summary

electroCore (Nasdaq: ECOR) announced the issuance of U.S. Patent No. 11,065,444 by the USPTO, covering a mobile phone method for trigeminal nerve stimulation to treat disorders like migraines. This patent details devices enabling self-treatment through non-invasive electrical stimulation. The handheld device targets nerves in the head to alleviate conditions, enhancing access to treatment. This patent expands electroCore's non-invasive pain management program, reinforcing its commitment to improving patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
none
Rhea-AI Summary

electroCore, Inc. (NASDAQ: ECOR) will report its financial results for the second quarter ending June 30, 2021, on August 5, 2021, after market close. A conference call and webcast for discussion will take place at 4:30 PM ET on the same day. electroCore focuses on bioelectronic medicine, utilizing a non-invasive vagus nerve stimulation therapy platform aimed at treating conditions like migraines and cluster headaches. The company emphasizes its commitment to enhancing patient outcomes through this innovative treatment approach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
-
Rhea-AI Summary

electroCore, Inc. (NASDAQ: ECOR) announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, will receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021. This award recognizes Dr. Staats' significant contributions to pain medicine, including over 450 published works. He has held leadership roles in various medical societies and is currently the President Elect of the World Institute of Pain. electroCore focuses on non-invasive vagus nerve stimulation therapies for migraine and cluster headache treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
Rhea-AI Summary

electroCore, Inc. (ECOR) expects approximately $1.3 million in revenue for Q2 2021, a 5% increase from Q1 2021 and a 69% growth year-over-year. The company reported a net cash usage of about $3.2 million for operations in the same period. As of June 30, 2021, cash and equivalents totaled approximately $23.7 million, which does not include $18.8 million raised in a recent offering. The company emphasizes ongoing operations and international expansion efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
Rhea-AI Summary

electroCore, Inc. (Nasdaq: ECOR) will be presenting at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 3:30 PM. CEO Dan Goldberger will provide a comprehensive overview of the company and engage in one-on-one meetings. Interested parties can access the presentation through the provided webcast link.

Following the event, a replay will be available in the Investor section of electroCore's website. The company specializes in non-invasive vagus nerve stimulation therapies aimed at treating cluster headaches and migraines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
conferences
-
Rhea-AI Summary

electroCore, Inc. (NASDAQ: ECOR) announced a public offering of 18 million shares at $1.00 each, raising approximately $18 million before expenses. The offering is expected to close around July 2, 2021. Underwriters have a 45-day option for an additional 2.7 million shares. Proceeds will support sales, marketing, working capital, and potential business expansions, although no specific acquisitions are currently planned. The offering is made under an effective shelf registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.13%
Tags
-
Rhea-AI Summary

electroCore, Inc. (NASDAQ: ECOR) announced a public offering of its common stock. The offering, which is subject to market conditions, aims to raise funds for sales, marketing, working capital, and potential acquisitions. The company will grant underwriters a 45-day option to purchase an additional 15% of shares. Ladenburg Thalmann & Co. Inc. is the sole book-runner, with Paulson Investment Company as co-manager. The offering will utilize an effective shelf registration statement filed with the SEC, and a preliminary prospectus will be available soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.13%
Tags
Rhea-AI Summary

On June 10, 2021, electroCore, Inc. (Nasdaq: ECOR) announced the publication of a peer-reviewed study in Communications Biology highlighting the positive effects of non-invasive vagus nerve stimulation (nVNS) on cognitive performance in sleep-deprived Air Force personnel. The trial found that nVNS improved throughput capacity by 10% compared to a sham treatment, with lasting effects. This research opens avenues for nVNS in both military and civilian settings, addressing fatigue-related cognitive impairments. The findings suggest potential market growth for gammaCore's applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of electroCore (ECOR)?

The current stock price of electroCore (ECOR) is $15.27 as of December 20, 2024.

What is the market cap of electroCore (ECOR)?

The market cap of electroCore (ECOR) is approximately 99.0M.

What is electroCore, Inc. known for?

electroCore, Inc. is renowned for its non-invasive vagus nerve stimulation (nVNS) technology used to treat various medical conditions and promote general wellbeing.

What products does electroCore offer?

electroCore's primary products include gammaCore for treating migraines and cluster headaches, and wellness devices like Truvaga and TAC-STIM.

Where is electroCore headquartered?

The company is headquartered in the United States, with additional offices in Germany, the UK, Italy, Australia, and Canada.

How has electroCore's financial performance been recently?

In 2023, electroCore reported net sales of $16 million, an 87% increase from 2022, driven by higher gammaCore sales and growing revenue from wellness products.

What conditions is gammaCore used to treat?

gammaCore is FDA cleared for the preventive and acute treatment of migraines and cluster headaches in adults, and is undergoing trials for other conditions like epilepsy and anxiety.

What is Truvaga?

Truvaga is a wellness device designed to enhance general wellbeing by using non-invasive vagus nerve stimulation to promote calmness, clarity, and better sleep.

Who are electroCore's target customers?

electroCore's target customers include patients suffering from neurological conditions, healthcare providers, and individuals seeking wellness solutions.

How does electroCore support its research and development?

electroCore invests in research and development to enhance its therapy delivery platforms, including integrating smartphone technologies for better patient accessibility.

What recent achievements has electroCore made?

Recent achievements include significant sales growth, new product developments, and ongoing clinical trials to expand the use of their nVNS technology.

How can I learn more about electroCore's latest news and updates?

For the latest news and updates, visit electroCore's official website at www.electrocore.com and explore their 'Investors' section.

electroCore, Inc.

Nasdaq:ECOR

ECOR Rankings

ECOR Stock Data

98.97M
4.91M
25.02%
16.11%
0.67%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ROCKAWAY